REPLY-S.P.A.
28.7.2017 14:02:11 CEST | Business Wire | Press release
Today, the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the results as at 30 June 2017.
Since the start of the year, the Group has recorded a consolidated turnover of €441.6 million, which is an increase of 14.3% compared to the same period in 2016.
In the first half of 2017, increased profit margins have also been recorded, with consolidated EBITDA of €61.7 million (+20.3%) and EBIT for the period of €57.0 million (+18.7%). Pre-tax profit amounted to €53.5 million, which represents an increase of 13.1% compared to 2016.
For the second quarter of the year, the Group's performance is equally positive, with consolidated turnover for the period of €233.2 million, which is an increase of 16.5% compared to 2016.
EBITDA, from April to June 2017, amounted to €33.7 million, with EBIT of €31.8 million and pre-tax profit of €28.1 million.
As at 30 June 2017, the Group's net financial position was positive for €35.3 million (€80.6 as at 31 March 2017). At 30 June 2016, the financial position has been positive for €23.3 million.
“In the first six months of 2017 - Mario Rizzante, Chairman of Reply, said at the end of the Board meeting -, Reply was able to achieve very positive results in terms of turnover and profit margins. In particular, the second quarter was noted for substantial growth, and this will enable us to look ahead with optimism over the upcoming months and continue to grow in line with the Group’s development path.”
Mario Rizzante continued: “Reply’s strength is its ability to interpret innovation by making it functional to businesses’ requirements. We are one of the first companies, for example, to work on the paradigms of Big Data, Cloud Computing, the Internet of Things and Augmented and Virtual Reality.”
Mario Rizzante concluded: “Today, the new frontier is represented by Artificial Intelligence and Machine Learning, technologies which all sectors of industry are introducing and in which Reply is significantly investing in specific solutions and expertise, to help businesses deal with the most substantial transformation over the new few years.”
The manager responsible for preparing the company's financial reports, Dr Giuseppe Veneziano, states in accordance with Paragraph 2 of Article 154-bis of the Consolidated Finance Act, that the accounting information contained in this press release corresponds to the company's records, ledgers and accounting entries.
Reply
Reply [MTA, STAR: REY] specialises in the design and
implementation of solutions based on new communication channels and
digital media. Reply is a network of highly specialised companies
supporting key European industrial groups operating in the telecom and
media, industry and services, banking, insurance and public
administration sectors in the definition and development of business
models enabled for the new paradigms of big data, cloud computing,
digital media and the Internet of Things. Reply services include:
Consulting, System Integration and Digital Services. www.reply.com
This press release is a translation, the Italian version will prevail.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170728005282/en/
Contact:
Media
Reply
Fabio Zappelli, Tel. +390117711594
f.zappelli@reply.com
or
Investor
Relation
Reply
Riccardo Lodigiani, Tel.
+390117711594
r.lodigiani@reply.com
or
Michael
Lueckenkoetter, Tel. +49524150091017
m.lueckenkoetter@reply.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Data4Industry-X Empowers Industrial Organizations in Meeting Digital Product Passport Requirements20.4.2026 14:17:00 CEST | Press release
Contributing to the International Manufacturing-X Council Showcase at Hannover Messe, to improve resilience, productivity and innovation in Manufacturing Hannover Messe - Data4Industry-X, the trusted industry data space solution, builds its momentum by accelerating Digital Product Passport (DPP) compliance with trusted, secure and traceable data exchange at scale, as demonstrated at Hannover Messe April 20-24, 2026 . As theDigital Product Passport becomes a regulatory reality for manufacturing organizations, the ability to exchange data in a trusted, secure and traceable environment across the entire supply chain, in compliance with data regulations such as the Data Act, has become critical. Actively contributing to the International Manufacturing-X Council showcase, driven by LNI 4.0 association involving 16 countries, Data4Industry-X, a decentralized environment, demonstrates the use case of the DPP on the battery’s State of Health, and how the battery current capacity and performanc
Ushio Industry & Entertainment Appoints Takuya Matsumoto as President & CEO and Outlines Strategic Direction for the Next Phase20.4.2026 12:32:00 CEST | Press release
Ushio Industry & Entertainment (Ushio INE GmbH) announces the appointment of Takuya Matsumoto as President and Chief Executive Officer, marking a key milestone in the evolution of the business and its integration within the Ushio Group. With more than 20 years of experience across sales, new business development, and global operations, Takuya Matsumoto brings deep industry expertise and a strong leadership track record within Ushio. Most recently, he served as General Manager of the Global Business Unit, where he played a pivotal role in advancing global growth initiatives. A Clear Vision: A strong heritage with a forward-looking vision focused on innovation, operational excellence, and customer value Under Takuya Matsumoto’s leadership, Ushio INE will continue to build on its strong legacy while advancing its mission to deliver high-performance, high-quality lighting solutions across industrial and entertainment markets worldwide. “Our mission is to continuously deliver essential ligh
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 202620.4.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 11am-12pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable response
PPG invests in testing line for radiation-curable coatings at Marly, France20.4.2026 11:00:00 CEST | Press release
Installation helps accelerate development cycles, reduce number of customer trials PPG (NYSE: PPG) today announced the installation of an advanced testing line for radiation-curable coatings at its R&D Center of Excellence in Marly, France. The line can test multiple curing technologies, including infrared (IR), ultraviolet (LED, excimer and arc lamps), and electron beam (EB). This investment allows the company to accurately replicate customer production conditions, helping accelerate development cycles and reduce the number of customer trials. Unlike conventional thermal curing, radiation curing requires less energy because it operates at or near ambient temperature. This reduction in energy demand can significantly lower carbon emissions by 65%*, with further gains possible when powered by renewable energy sources. In addition, UV- and EB-curable systems typically use 100% solids formulations with no solvents, reducing or eliminating volatile organic compound emissions. Beyond sustai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
